The present findings indicate that patients with NAFLD or MAFLD (no eligible study with a MASLD diagnosis was identified) exhibit higher circulating ANGPTL8 levels compared to controls, highlighting the potential of circulating ANGPTL8 as an additional novel biomarker for steatosis/steatohepatitis. This evidence concerns the gene ANGPTL8 and metabolic dysfunction-associated steatotic liver disease.